AnaptysBio Inc.
Organization details
- Legal name
- AnaptysBio Inc.
- Former names
- Anaptys Biosciences Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- June
- Ticker symbol
- ANAB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001370053
- EIN
- 20-3828755
Board of directors
-
Daniel Faga · Director · President, CEOSince 2023
-
Dennis M. Fenton · DirectorSince 2023
-
Hollings Renton · DirectorSince 2023
-
J. Anthony Ware · DirectorSince 2023
-
James N. Topper · DirectorSince 2023
-
John A. Orwin · DirectorSince 2023
- Since 2023
-
Laura Hamill · DirectorSince 2023
- Since 2023
-
Oleg Nodelman · DirectorSince 2025
-
Owen Hughes · DirectorSince 2026
- Since 2023
-
Susannah Gray · DirectorSince 2026
Chief executives
Director election results
Annual meeting of August 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
69.8%
-
92.7%
Board connections
13 of this board's directors also sit on 26 other boards. 25 are in the same sector.
-
First Tracks Biotherapeutics Inc. Same sectorvia Daniel Faga, Dennis M. Fenton, J. Anthony Ware, John A. Orwin, John P. Schmid, Magda Marquet and Rita Jain
-
Zymeworks Inc. Same sectorvia Hollings Renton and Oleg Nodelman
-
4D Molecular Therapeutics Inc. Same sectorvia Susannah Gray
-
Aktis Oncology Inc. Same sectorvia Oleg Nodelman
-
Arcturus Therapeutics Holdings Inc. Same sectorvia Magda Marquet
-
Attovia Therapeutics Inc. Same sectorvia James N. Topper
-
Avalo Therapeutics Inc. Same sectorvia Rita Jain
-
BlossomHill Therapeutics Inc. Same sectorvia John P. Schmid
-
BridgeBio Oncology Therapeutics Inc. Same sectorvia John P. Schmid
-
C4 Therapeutics Inc. Same sectorvia Owen Hughes
-
Celldex Therapeutics Inc. Same sectorvia Rita Jain
-
Design Therapeutics Inc. Same sectorvia John P. Schmid
-
Fate Therapeutics Inc. Same sectorvia Laura Hamill
- via John P. Schmid
-
ImageneBio Inc. Same sectorvia Owen Hughes
-
Immix Biopharma Inc. Same sectorvia Magda Marquet
-
Jazz Pharmaceuticals plc Same sectorvia Laura Hamill
-
Maravai LifeSciences Holdings Inc. Same sectorvia Susannah Gray
-
NewAmsterdam Pharma Company N.V. Same sectorvia James N. Topper
-
Nuvation Bio Inc. Same sectorvia Oleg Nodelman
-
Phathom Pharmaceuticals Inc. Same sectorvia James N. Topper
-
SAB Biotherapeutics Inc. Same sectorvia Rita Jain
-
Scilex Holding Company Same sectorvia Laura Hamill
-
TransCode Therapeutics Inc. Same sectorvia Magda Marquet
-
Travere Therapeutics Inc. Same sectorvia John A. Orwin
-
Xeris Biopharma Holdings Inc. Same sectorvia John P. Schmid
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $9,752,298
- 42 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 1, 2026 | Hollings Renton Director | Option exercise | +5,000 | $18.03 | $90,150 |
| Oct 1, 2026 | Hollings Renton Director | Open-market sale | −5,000 | $49.87 | $249,372 |
| Sep 15, 2026 | John A. Orwin Director | Option exercise | +1,300 | — | — |
| Jun 15, 2026 | John P. Schmid Director | Option exercise | +6,030 | — | — |
| Jun 15, 2026 | Hollings Renton Director | Option exercise | +6,030 | — | — |
| Jun 15, 2026 | John A. Orwin Director | Option exercise | +6,030 | — | — |
| Mar 30, 2026 | John P. Schmid Director | Open-market sale | −12,596 | $55.71 | $701,723 |
| Mar 30, 2026 | John P. Schmid Director | Open-market sale | −7,527 | $56.70 | $426,781 |
| Mar 30, 2026 | John P. Schmid Director | Open-market sale | −522 | $57.40 | $29,963 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −510 | $56.61 | $28,871 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −2,570 | $57.91 | $148,829 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −3,662 | $58.62 | $214,666 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −490 | $59.62 | $29,214 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −550 | $60.63 | $33,347 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −1,012 | $62.15 | $62,896 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about AnaptysBio Inc.
Who is the CEO of AnaptysBio Inc.?
Daniel Faga is AnaptysBio Inc.'s Interim CEO.
How many directors are on AnaptysBio Inc.'s board?
AnaptysBio Inc.'s board has 13 directors: Daniel Faga, Dennis M. Fenton, Hollings Renton, J. Anthony Ware, James N. Topper, John A. Orwin, John P. Schmid, Laura Hamill, Magda Marquet, Oleg Nodelman and 3 others.
Are AnaptysBio Inc. insiders buying or selling shares?
Over the last 12 months, AnaptysBio Inc. insiders made no open-market purchases and sold $9.8 million of shares in 42 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="anaptysbio-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.